Immatics Biotechnologies Net Income vs. Cash Flow From Operations
| IMTXW Stock | USD 0.50 0.10 25.00% |
Net Loss | First Reported 2018-03-31 | Previous Quarter -18 M | Current Value -8.6 M | Quarterly Volatility 38.1 M |
For Immatics Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immatics Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well immatics biotechnologies GmbH utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immatics Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of immatics biotechnologies GmbH over time as well as its relative position and ranking within its peers.
Immatics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics Biotechnologies. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.766 | Quarterly Revenue Growth (0.16) | Return On Assets (0.12) | Return On Equity (0.24) |
The market value of Immatics Biotechnologies is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Immatics Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics Biotechnologies' market value can be influenced by many factors that don't directly affect Immatics Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immatics Biotechnologies Cash Flow From Operations vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immatics Biotechnologies's current stock value. Our valuation model uses many indicators to compare Immatics Biotechnologies value to that of its competitors to determine the firm's financial worth. immatics biotechnologies GmbH is rated fifth overall in net income category among its peers. It is currently regarded as number one stock in cash flow from operations category among its peers . Immatics Biotechnologies reported Net Loss of (96.99 Million) in 2023. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immatics Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Immatics Cash Flow From Operations vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Immatics Biotechnologies |
| = | (96.99 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Immatics Biotechnologies |
| = | 18.23 M |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Immatics Cash Flow From Operations Comparison
Immatics Biotechnologies is currently under evaluation in cash flow from operations category among its peers.
Immatics Biotechnologies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immatics Biotechnologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immatics Biotechnologies will eventually generate negative long term returns. The profitability progress is the general direction of Immatics Biotechnologies' change in net profit over the period of time. It can combine multiple indicators of Immatics Biotechnologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.6 M | -1.7 M | |
| Net Interest Income | 13 M | 13.7 M | |
| Interest Income | 13.8 M | 14.5 M | |
| Operating Income | -101.7 M | -96.6 M | |
| Net Loss | -97 M | -101.8 M | |
| Income Before Tax | -97 M | -101.8 M | |
| Total Other Income Expense Net | 4.7 M | 5 M | |
| Net Loss | -97 M | -101.8 M | |
| Income Tax Expense | 831 K | 573.8 K | |
| Net Loss | (1.20) | (1.26) | |
| Income Quality | (0.19) | (0.18) | |
| Net Income Per E B T | 1.03 | 1.07 |
Immatics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immatics Biotechnologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immatics Biotechnologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immatics Biotechnologies' important profitability drivers and their relationship over time.
Use Immatics Biotechnologies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immatics Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immatics Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Immatics Biotechnologies Pair Trading
immatics biotechnologies GmbH Pair Trading Analysis
The ability to find closely correlated positions to Immatics Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immatics Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immatics Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling immatics biotechnologies GmbH to buy it.
The correlation of Immatics Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immatics Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immatics Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immatics Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immatics Biotechnologies position
In addition to having Immatics Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Value Funds Thematic Idea Now
Small Value Funds
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.